Abstracts tagged "Animal models"

Abstract Number: 559 • 2013 ACR/ARHP Annual Meeting
Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus
Marta Mosca¹, Chiara Tani², Sabrina Vagnani³, Linda Carli^3,4, Rosaria Talarico⁵, Chiara Baldini⁵, Stefano Bombardieri³ and Agostino Virdis⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴GenOMeC PhD, University of Siena, Siena, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Italy, ⁶Department of Clinical and Experimental Medicine. University of Pisa, Hypertension Unit, University of Pisa, Pisa, Italy
Background/Purpose: Antimalarial drugs are a cornerstone of treatment of systemic lupus erythematosus (SLE). It has been suggested that antimalarial drugs may have a protective effect…
Abstract Number: 148 • 2013 ACR/ARHP Annual Meeting
Microarray Analysis Of Synovial Specimen of Early Human (CHECK) and Experimental Osteoarthritis to Identify Pathways and Processes Associated with Pathology
Arjen B. Blom¹, Peter L. van Lent², Martijn H. van den Bosch¹, Hans Cats³, Frank H.J. van den Hoogen⁴, Peter M. van der Kraan⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Rheumatology Centre Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: The majority of osteoarthritis (OA) patients show synovial inflammation, even relatively early during the disease. We used microarray analysis of synovial tissue of early…
Abstract Number: 2215 • 2013 ACR/ARHP Annual Meeting
Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis
Sylvain Perruche¹, Amandine Clauzon¹, Francis Bonnefoy¹, Eric Toussirot² and Philippe Saas³, ¹UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, ²Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ³Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France
Background/Purpose: Most of the currently available biological agents used in the treatment of rheumatoid arthritis (RA) target a cellular or soluble factor involved in the…
Abstract Number: 1294 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model
Romina R. Riveiro-Naveira¹, Jesus Loureiro¹, Alberto Centeno-Cortés², Eduardo López-Peláez², Carlos Vaamonde-García¹, M. Noa Valcárcel-Ares¹, Francisco J. Blanco³ and Maria J. López-Armada¹, ¹Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, ²Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, ³Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: Inflammatory cells like macrophages, lymphocytes and neutrophils in hyperplasic synovial tissue have been identified as key players in the onset and development of rheumatoid…
Abstract Number: 526 • 2013 ACR/ARHP Annual Meeting
Endochondral Bone Formation and Advanced Enthesitis Are Key Features Of Proteoglycan Induced Spondylitis Mouse Model Of Ankylosing Spondylitis
Gethin P Thomas¹, Hsu-Wen Tseng², Allison Pettit^3,4, Tibor T. Glant⁵, Allan McRae² and Matthew A. Brown⁶, ¹Translational Reserch Institute, University of Queensland Diamantina Institute, Woolloongabba, Australia, ²University of Queensland Diamantina Institute, Woolloongabba, Australia, ³Mater Research, Woolloongabba, Australia, ⁴University of Queensland Centre for Clinical Research, Herston, Australia, ⁵Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ⁶University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Transition from an initial inflammatory phase to the disabling osteoproliferative phase in ankylosing spondylitis (AS) is very poorly understood. Elucidation of the mechanisms underlying…
Abstract Number: 2216 • 2013 ACR/ARHP Annual Meeting
Tubastatin A, a Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction In a Collagen Antibody-Induced Arthritis Mouse Model
Joong Kyong Ahn¹, Jaejoon Lee², Hyemin Jeong², Jiwon Hwang², Seulkee Lee², Ji Young Chai³, Inyoung Kim^2,4, Eun Chung Hong⁵, Eun-Kyung Bae⁵, Hoon-Suk Cha² and Eun-Mi Koh², ¹Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ⁴MD, Seoul, South Korea, ⁵Samsung Biomedical Research Institute, Seoul, South Korea
Background/Purpose: Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylasing histones, and HDAC inhibitors induce various cellular effects, including apoptosis, cell…
Abstract Number: 1295 • 2013 ACR/ARHP Annual Meeting
Mechanisms For Fostamatinib-Induced Blood Pressure Elevation
Matthew Skinner¹, Karen Philp¹, David Lengel², Lucy Coverley¹, Eva Lamm Bergstroem³, Philip Glaves¹, Helen Musgrove¹, Helen Prior¹, Martin Braddock⁴, Russell Huby¹, Jon O Curwen¹, Paul Duffy¹ and Alex Harmer¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²AstraZeneca R&D Waltham, Waltham, MA, ³AstraZeneca R&D Mölndal, Mölndal, Sweden, ⁴AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom
Background/Purpose: Fostamatinib is a kinase inhibitor with activity at spleen tyrosine kinase. In clinical studies in patients with rheumatoid arthritis, fostamatinib treatment was associated with…
Abstract Number: 536 • 2013 ACR/ARHP Annual Meeting
Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation
Leonie M. van Duivenvoorde¹, Melissa N. van Tok¹ and Dominique L. Baeten², ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The morbidity of spondyloarthritis (SpA) is determined not only by inflammation but also by structural damage, in particular osteoproliferation leading to joint ankylosis. The…
Abstract Number: 2223 • 2013 ACR/ARHP Annual Meeting
Monitoring Of Active Matrix Metalloproteinase-3 Using
Sung Jae Choi¹, Young Ho Seo², Young Ho Lee³, Jong Dae Ji¹, Gwan Gyu Song⁴, Aeju Lee² and Jae-Hoon Kim⁴, ¹Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Rheumatology, Korea University Medical center, Seoul, South Korea, ³Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea
Background/Purpose: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active…
Abstract Number: 1249 • 2013 ACR/ARHP Annual Meeting
Contrasting Pathophysiology and Behavioural Responses Associated With Osteoarthritis and An Inflammatory Arthropathy
Sanaa Zaki¹, Margaret M. Smith², Susan Smith¹, Mark Connor³ and Christopher B. Little², ¹Raymond Purves Bone and Joint Research Laboratories, University of Sydney, St Leonards, Australia, ²Raymond Purves Bone and Joint Research Labs, University of Sydney, St Leonards, Australia, ³Australian School of Advanced Medicine, Macquarie University, North Ryde, Australia
Background/Purpose: Osteoarthritis (OA) affects more than 15% of the population, and is the major cause of disability in people over 60. There are no therapies…
Abstract Number: 83 • 2013 ACR/ARHP Annual Meeting
Oleuropein Or Rutin Consumption Decreases The Spontaneous Development Of OA In Hartley Guinea Pig
Christelle Sanchez¹, Marie-Noëlle Horcajada², Fanny Membrez Scalfo², Pierre Drion³, Fanny Comblain⁴, Elizabeth Offord² and Yves Henrotin⁴, ¹Bone and Cartilage Research Unit, University of Liège, Liege, Belgium, ²Nutrition and Health Department, Nestle Research Center, Lausanne, Switzerland, ³GIGA CHU animal facilities, University of Liège, Liège, Belgium, ⁴Bone and Cartilage Research Unit, University of Liège, Liège, Belgium
Background/Purpose: To assess the potential protective effect of oleuropein and rutin, two polyphenols found in olive oil, fruits or vegetables, on osteoarthritis development Methods: Sixty…
Abstract Number: 2228 • 2013 ACR/ARHP Annual Meeting
FMS-Like Tyrosine Kinase 3 Ligand -Dependent CD103+DC Are Crucial For The Initiation Of Collagen-Induced Arthritis
Maria Ines Ramos¹, Samuel Garcia², Saïda Aarrass¹, Boy Helder³, Kris A. Reedquist⁴, Paul-Peter Tak⁵ and Maria C. Lebre¹, ¹Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experiemental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Dendritic cells (DCs) are a heterogeneous cell population that plays an important role for the initiation of protective and pathogenic immunity. Flt3L is a…
Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 84 • 2013 ACR/ARHP Annual Meeting
New Formulation With Potential To Prevent and Treat Osteoporosis and Osteoarthritis
A. Torrent¹, E. Montell², J. Vergés¹, P. Dalmau³, R. Ruhí³, M.C. Carceller⁴, A. Blanco⁴, M.C. Terencio⁴, M.L. Ferrándiz⁴ and M.J. Alcaraz⁵, ¹Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain, ²Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain, ³Technological Extraction Dept, BIOIBERICA S.A., Palafolls, Spain, ⁴Department of Pharmacology and IDM, University of Valencia, Burjassot, Spain, ⁵University of Valencia, Burjasot, Valencia, Spain
Background/Purpose: Osteoarthritis (OA) is a multidimensional disease that affects all anatomical joint structures, particularly cartilage, synovium and subchondral bone. In turn, osteoporosis (OP) is a…
Abstract Number: 2903 • 2013 ACR/ARHP Annual Meeting
Perturbed Response To Experimental Renal Injury In a TGFβ Dependent Mouse Model Of Scleroderma
Emma Derrett-Smith¹, Mark Neal², David J. Abraham³, Alan Salama⁴, Mark A. Little² and Christopher P. Denton³, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²UCL Medical School, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Centre for Nephrology, University College London, London, United Kingdom
Background/Purpose: Scleroderma renal pathology is predominantly vascular and fibrotic without major inflammatory features. Accelerated hypertension and rapidly progressive renal dysfunction are hallmarks of scleroderma renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].